Docoh
Loading...

NOTV Inotiv

Bioanalytical Systems, Inc., operating as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market.

Company profile

Ticker
NOTV, BASI
Exchange
Website
CEO
Jacqueline Lemke
Employees
Incorporated
Location
Fiscal year end
Former names
BIOANALYTICAL SYSTEMS INC
SEC CIK
IRS number
351345024

NOTV stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 Feb 21
13 Apr 21
30 Sep 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Sep 20 Sep 19 Sep 18 Sep 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Inotiv earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.16M 1.16M 1.16M 1.16M 1.16M 1.16M
Cash burn (monthly) 83.67K (positive/no burn) (positive/no burn) 128.17K (positive/no burn) (positive/no burn)
Cash used (since last report) 289.03K n/a n/a 442.76K n/a n/a
Cash remaining 865.97K n/a n/a 712.24K n/a n/a
Runway (months of cash) 10.4 n/a n/a 5.6 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Apr 21 Neff R Matthew Common Shares Grant Aquire A No No 0 2,683 0 61,113
1 Apr 21 Davis Gregory Cole Common Shares Grant Aquire A No No 0 2,683 0 32,683
1 Apr 21 Johnson Richard Allen Common Shares Grant Aquire A No No 0 2,683 0 42,683
5 Mar 21 Beth Taylor Common Shares Buy Aquire P No No 17.7 5,000 88.5K 34,295
1 Mar 21 John Gregory Beattie Common Shares Buy Aquire P No No 18.6 1,712 31.84K 25,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

23.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 22 17 +29.4%
Opened positions 9 5 +80.0%
Closed positions 4 4
Increased positions 1 4 -75.0%
Reduced positions 4 4
13F shares
Current Prev Q Change
Total value 31.96M 5.61M +470.1%
Total shares 2.6M 1.17M +121.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Iszo Capital 760.02K $9.35M NEW
Iszo Capital Management 760.02K $9.35M NEW
Renaissance Technologies 600.07K $7.38M +20.0%
Vanguard 147.16K $1.81M -71.7%
Bridgeway Capital Management 67.51K $830K 0.0%
Private Advisor 64.5K $793K NEW
California Public Employees Retirement System 51.2K $630K NEW
Next Century Growth Investors 43.46K $534K NEW
BLK Blackrock 30.7K $377K -0.1%
EAM Investors 21.96K $270K NEW
Largest transactions
Shares Bought/sold Change
Iszo Capital 760.02K +760.02K NEW
Iszo Capital Management 760.02K +760.02K NEW
Vanguard 147.16K -373.03K -71.7%
Renaissance Technologies 600.07K +100.05K +20.0%
Private Advisor 64.5K +64.5K NEW
California Public Employees Retirement System 51.2K +51.2K NEW
Next Century Growth Investors 43.46K +43.46K NEW
EAM Investors 21.96K +21.96K NEW
UBS UBS Group AG - Registered Shares 1.32K -11.01K -89.3%
Millennium Management 10.37K +10.37K NEW
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: academic, Biocraft, CEO, clarification, clarifying, Codification, Committee, context, decision, Director, efficient, explicit, exploring, extend, fact, Food, forgivable, formal, formation, high, implicit, low, mission, nondeductible, overhead, pending, pharmacology, proposed, quickly, reflecting, replace, reversed, revolutionary, ROU, Royalty, satisfaction, study, superior, surgery, Teva, therapeutic, treat, variable
Removed: accompanied, accomplish, active, addressed, advantage, aggressively, agro, agrochemical, amortized, application, approach, arising, assessment, beneficiary, boost, borrowing, branding, calculated, candidate, capitalization, capitalized, chose, classification, closed, collateralized, competitive, complementary, conducted, consisting, constituted, consult, consultative, consumable, continued, culture, deliver, developed, developing, diligence, discounted, disposition, distinguish, emphasize, enter, entitled, escrow, evidenced, evolving, excellence, excellent, excluded, exercised, existed, expanding, expedient, expiration, expired, extensive, facilitate, Fifty, filing, forward, fruition, fulfillment, grown, highly, image, implementing, inclusion, indemnification, indemnity, indirect, industrial, initially, install, integrated, integration, intend, intended, international, intrinsic, invest, invested, labor, landlord, largely, launching, leading, length, level, longer, mammalian, manufactured, Maryland, member, minimum, mix, modified, move, newly, obtaining, offered, ongoing, operate, Oriole, owed, party, people, performing, personal, plant, practical, practice, preliminary, present, produce, pronouncement, proprietary, prospective, qualify, recruited, recruitment, recurring, regulated, reimbursement, relationship, released, responsible, retention, retrospective, reviewing, separate, shipment, similar, site, slightly, solidify, sponsor, standard, state, statute, streamline, structure, sublessee, talented, tenant, touch, transfer, transition, turnover, updated, upgrade, visibility, vision, warranty, web